A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
about
Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium studyCombination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.Myeloablative chemotherapy with autologous bone marrow rescue in children and adolescents with recurrent malignant astrocytoma: outcome compared with conventional chemotherapy: a report from the Children's Oncology Group.Phase 1 study of oxaliplatin and irinotecan in pediatric patients with refractory solid tumors: a children's oncology group studyRandomized phase II window trial of two schedules of irinotecan with vincristine in patients with first relapse or progression of rhabdomyosarcoma: a report from the Children's Oncology Group.Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models.Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study.A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.Dose escalation of intravenous irinotecan using oral cefpodoxime: a phase I study in pediatric patients with refractory solid tumorsSuccessful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin.Multi-tyrosine kinase inhibitors in preclinical studies for pediatric CNS AT/RT: Evidence for synergy with Topoisomerase-I inhibition.Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.Phase I and Phase II Objective Response Rates are Correlated in Pediatric Cancer Trials: An Argument for Better Clinical Trial EfficiencyNo topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecanTyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.Pharmacogenomics of second-line drugs used for treatment of unresponsive or relapsed osteosarcoma patients.Case Study of a Young Adult With Ewing Sarcoma.
P2860
Q33382930-6B9C47C0-7524-452B-8261-5F4FECF64427Q33438641-DC00C88C-E2F5-4812-A387-26359171653BQ33747635-9CCB3DE9-7A42-466A-94ED-D1A129952964Q33964850-EFFFF94C-FF5A-4E90-B569-DC076DF44646Q34281235-2BE6E95B-151E-44B2-9FA0-36B495EA1795Q34344177-D5DD2AB5-1B8E-4450-A538-F9397296E725Q34679179-204DF973-EAC7-4884-8997-D432A374B09AQ34872658-E6148DE6-17DE-4189-8E12-D439CE932B15Q35667216-986C4CF5-BA26-40D6-8258-0B278FD8AF51Q35688335-D65DD739-2301-473C-A792-AF1387D9880DQ35753503-E9D81796-5043-49A0-9625-A237C2A238B2Q36036684-274393B6-C540-4E0E-835A-97E43DB1D728Q37048013-695D1823-BA07-4ACD-B1F2-3240A75E2FC9Q37355466-5DC9421D-1E4B-4A8C-91B0-AA46DA8DEE54Q37369825-DB25243B-3462-40B6-ACE8-8CB50EB077F7Q37662264-E01FF449-FF89-4AD4-B834-E6C881376F8BQ38791215-F393EB53-81DF-4D37-8089-E6A77E07C748Q55312953-E2959556-1956-4C56-86C6-E3AE002A99A4
P2860
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@ast
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@en
type
label
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@ast
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@en
prefLabel
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@ast
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@en
P2093
P1476
A phase I study of irinotecan in pediatric patients: a pediatric oncology group study.
@en
P2093
J Sullivan
L Luchtman-Jones
M Bernstein
P407
P577
2001-01-01T00:00:00Z